Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisPatricia Cortazar, Gϋnter von Minckwitz, Holger Eidtmann et al.|The Lancet|2014Cited by 4.7k
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized studyLuca Gianni, Giuseppe Viale|Annals of Oncology|2022Cited by 382
30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort studyGianni Bonadonna, Pinuccia Valagussa, Angela Moliterni et al.|BMJ|2005Cited by 252
Phase III Trial Evaluating the Addition of Paclitaxel to Doxorubicin Followed by Cyclophosphamide, Methotrexate, and Fluorouracil, As Adjuvant or Primary Systemic Therapy: European Cooperative Trial in Operable Breast CancerLuca Gianni, Gianni Bonadonna, José Baselga et al.|Journal of Clinical Oncology|2009Cited by 216
Feasibility and Tolerability of Sequential Doxorubicin/Paclitaxel Followed by Cyclophosphamide, Methotrexate, and Fluorouracil and Its Effects on Tumor Response as Preoperative TherapyLuca Gianni, José Baselga, W. Eiermann et al.|Clinical Cancer Research|2005Cited by 165